TP53 and B-cell chronic lymphocytic leukemia: Ex vivo human CLL B cells, but not the residual T lymphocytes of the same patients, were killed by mtKv1.3-targeting agents even when anti-apoptotic Bcl-2 was overexpressed and the tumor suppressor p53 was mutated [32].